Optomed’s Interim report, January – September 2023
Optomed Plc Stock Exchange Release 3 November 2023 at 9:00, Helsinki
Optomed Plc: Interim report, January – September 2023
July – September 2023
- Revenue increased by 14.0 percent to EUR 4.2 (3.7) million.
- Devices segment revenue increased by 7.5 percent to EUR 1.8 (1.7) million due to increased distributor sales.
- Software segment revenue increased by 19.4 percent to EUR 2.4 (2.0) million driven by strong healthcare solution sales.
- Adjusted EBITDA amounted to EUR 0.3 (0.1) million corresponding to 6.2 (3.9) percent of revenue. EBITDA amounted to EUR -0.0 (0.1) million. The comparison period both EBITDA and Adjusted EBITDA were positively affected by a EUR 0.8 million loan waiver.
- Record-breaking cash flow from operating activities amounted to EUR 767 (-504) thousand.
- Juho Himberg started as the CEO on 1 October 2023.
- Optomed successfully completed directed share issue raising gross proceeds of EUR 4.3 million.
- Outlook unchanged: Optomed expects its full year 2023 revenue to grow compared to 2022.
January – September 2023
- Revenue increased by 7.4 percent to EUR 11.4 (10.6) million.
- Devices segment revenue decreased by 3.3 percent to EUR 4.0 (4.1) million.
- Software segment revenue increased by 14.2 percent to EUR 7.5 (6.5) million.
- Adjusted EBITDA amounted to EUR -0,7 (-1,6) million corresponding to -6.2 (-15.1) percent of revenue.
Key figures
EUR, thousand | Q3/2023 | Q3/2022 | Change, % | Q1-Q3/2023 | Q1-Q3/2022 | Change, % | 2022 |
Revenue | 4,218 | 3,700 | 14.0% | 11,440 | 10,648 | 7.4% | 14,660 |
Gross profit * | 2,841 | 2,967 | -4.2% | 7,803 | 7,305 | 6.8% | 10,069 |
Gross margin % * | 67.4% | 80.2% | 68.2% | 68.6% | 68.7% | ||
EBITDA | -48 | 145 | -133.2% | -1,024 | -1,604 | 36.2% | -1,952 |
EBITDA margin *, % | -1.1% | 3.9% | -8.9% | -15.1% | -13.3% | ||
Adjusted EBITDA * | 263 | 145 | 80.9% | -713 | -1,604 | 55.6% | -1,952 |
Adjusted EBITDA margin *, % | 6.2% | 3.9% | -6.2% | -15.1% | -13.3% | ||
Operating result (EBIT) | -603 | -1,411 | 57.3% | -2,655 | -4,227 | 37.2% | -5,097 |
Operating margin (EBIT) *, % | -14.3% | -38.1% | -23.2% | -39.7% | -34.8% | ||
Adjusted operating result (EBIT) * | -291 | -1,411 | 79.3% | -2,343 | -4,227 | 44.6% | -5,097 |
Adjusted operating margin (EBIT margin) *, % | -6.9% | -38.1% | -20.5% | -39.7% | -34.8% | ||
Net profit/ loss | -439 | -1,377 | 68.1% | -2,911 | -4,075 | 28.6% | -5,472 |
Earnings per share | -0.03 | -0.10 | 71.9% | -0.18 | -0.29 | 37.1% | -0.37 |
Cash flow from operating activities | 767 | -504 | 252.2% | -120 | -2,093 | 94.3% | -2,370 |
Net Debt | -4,890 | -271 | 1,707.5% | -4,890 | -271 | 1,707.5 % | -3,251 |
Net debt/ EBITDA (LTM) * | 3.6 | 0.1 | 3.6 | 0.1 | 1.7 | ||
Net debt/ Adjusted EBITDA (LTM) * | 4.6 | 0.1 | 4.6 | 0.1 | 1.7 | ||
Equity ratio * | 68.9% | 63.3% | 68.9% | 63.3% | 65.0% | ||
R&D expenses personnel | 297 | 251 | 18.0% | 942 | 850 | 10.9% | 1,198 |
R&D expenses other costs | 192 | 124 | 55.2% | 505 | 480 | 5.4% | 661 |
Total R&D expenses | 489 | 375 | 30.3% | 1,447 | 1,329 | 8.9% | 1,859 |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
Optomed presents Adjusted EBITDA and Adjusted operating result as alternative performance measures to enhance comparability of business performance between reporting periods. In July-September 2023, items affecting comparability amounted to EUR 311 thousand and related to increased credit risk with respect to an overdue trade receivable from a customer in China.
CEO Review
Optomed had a great third quarter and I’m very delighted about our performance. Our results were beyond satisfactory. During the quarter, we received among others large customer orders from Spain and China that provide future growth potential in both regions.
In the face of challenges, our team’s dedication and strategic execution have propelled us beyond merely satisfactory outcomes. Key financial metrics, including cash flow from operating activities and adjusted EBITDA reflect the effectiveness of our initiatives. When comparing results to the previous year it is important to highlight that during the quarter Optomed received a loan waiver in the amount of EUR 841 thousand that was treated as other operating income and, therefore, affecting third quarter results positively.
While our success in Q3 is gratifying, I must also address the situation of the FDA clearance for our AI fundus camera Optomed Aurora AEYE. At this point, there are no further updates. We are actively collaborating with our partners and regulatory authorities to expedite the clearance process.
Looking forward, we are energized by the momentum gained and remain steadfast in our pursuit of excellence. Our shareholders continued trust and investment are pivotal to our success, and we are dedicated to delivering sustained value. We remain optimistic but cautious.
Thank you for your confidence in our company.
Juho Himberg,
CEO
Outlook 2023
Optomed expects its full year 2023 revenue to grow compared to 2022.
Telephone conference
A telephone conference for analysts, investors and media will be arranged on 3 November 2023 at 11.00 EET, (10.00 CET). The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.
The participants are requested to register for the call-in advance by email to sakari.knuutti@optomed.com.
Please see the call-in numbers below:
FI +358 9 856 263 00
SE +46 8 505 218 52
UK +44 20 3321 5273
US +1 646 838 1719
FR +33 1 70 99 53 92
The conference id is 197 712 168#.
Please note that by dialing into the conference call, the participant agrees that personal information such as name and company name will be collected.
Group performance
July – September 2023
In July-September 2023, Group revenue increased by 14.0 percent to EUR 4,218 (3,700) thousand. Devices segment revenue increased by 7.5 percent to EUR 1,825 (1,697) thousand. The Software segment revenue increased by 19.4 percent to EUR 2,393 (2,003) thousand. All sales channels in both Software and Devices segments performed well, except for OEM sales channel.
In July-September 2023, the gross margin decreased to 67.4 from 80.2 percent of last year. During the comparison period, the gross margin was negatively affected by an inventory provision of EUR 200 thousand, and Optomed was granted a loan waiver in the amount of EUR 841 thousand treated as other operating income and, therefore, affecting the gross margin positively. The gross margin for the third quarter of 2023 adjusted for grants and other operating income is 68.2 percent compared to comparison period 57.4 percent.
EBITDA decreased and it was EUR -48 (145) thousand and adjusted EBITDA was EUR 263 (145) thousand. The comparison period EBITDA was positively affected by the previously mentioned loan waiver.
EBIT improved and it was EUR -603 (-1,411) thousand and adjusted EBIT was EUR -291 (-1,411) thousand.
In July-September 2023, net financial items amounted to EUR 144 (15) thousand and consisted mainly of interest payments to financial institutions and the translation effect of CNY and USD to EUR.
January – September 2023
In January-September 2023, Group revenue increased by 7.4 percent to EUR 11,440 (10,648) thousand. The growth was driven by the Software segment as the Devices segment’s revenue decreased by 3.3 percent while the Software segment’s revenue increased by 14.2 percent.
The gross margin decreased to 68.2 percent from 68.6 percent last year.
EBITDA amounted to EUR -1,024 (-1,604) thousand and adjusted EBITDA was EUR -713 (-1,604) thousand.
EBIT was EUR -2,655 (-4,227) thousand and adjusted EBIT was EUR -2,343 (-1,604) thousand. The improvement is due to the combination of improved gross profit and decreased OPEX.
Net financial items amounted to EUR -315 (92) thousand and consisted mainly of interest payments to financial institutions and the translation effect of CNY and USD to EUR.
Cash flow and financial position
July – September 2023
In July-September 2023, the cash flow from operating activities amounted to EUR 767 (-504) thousand. Net cash used in investing activities was EUR -615 (-797) thousand and relates to capitalized development expenses. Net cash from financing activities amounted to EUR 3,721 (-172) thousand. Optomed completed a directed share issue consisting of 1,589,042 shares and collected gross proceeds of approximately EUR 4.3 million in September 2023.
Consolidated cash and cash equivalents at the end of the period amounted to EUR 9,565 (5,668) thousand. Interest-bearing net debt was EUR -4,890 (-271) thousand at the end of the period.
Net working capital was EUR 2,802 (4,138) thousand at the end of the period.
Optomed has large trade receivables from a Chinese customer. The customer missed a payment during the quarter and, consequently, the specific loss allowance weighted average loss rate was increased from 30% to 50%, which reflects an increase of EUR 311 thousand. The total amount of the receivable in the balance sheet is now EUR 778 thousand.
January – September 2023
In January-September 2023, the cash flow from operating activities amounted to EUR -120 (-2,093) thousand.
Net cash used in investing activities was EUR -1,828 (-2,471) thousand and relates to capitalized development expenses.
Net cash from financing activities amounted to EUR 3,024 (3,380) thousand.
Devices segment
Optomed has two synergistic business segments: Devices and Software.
The Devices segment develops, commercializes, and manufactures easy-to-use, and affordable handheld fundus cameras, that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma and AMD (Age Related Macular Degeneration).
EUR, thousand | Q3/2023 | Q3/2022 | Change, % | Q1-Q3/2023 | Q1-Q3/2022 | Change, % | 2022 |
Revenue | 1,825 | 1,697 | 7.5% | 3,986 | 4,122 | -3.3% | 5,398 |
Gross profit * | 1,124 | 1,592 | -29.4% | 2,356 | 2,875 | -18.0% | 3,738 |
Gross margin % * | 61.6% | 93.8% | 59.1% | 69.7% | 69.3% | ||
EBITDA | -50 | 546 | -109.2% | -693 | -417 | -66.2% | -670 |
EBITDA margin *, % | -2.7% | 32.2% | -17.4% | -10.1% | -12.4% | ||
Operating result (EBIT) | -413 | -844 | 51.1% | -1,769 | -2,550 | 30.6% | -3,159 |
Operating margin (EBIT) *, % | -22.6% | -49.7% | -44.4% | -61.9% | -58.5% |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
July-September 2023
In July-September 2023, the Devices segment revenue increased by 7.5 percent to EUR 1,825 (1,697) thousand. The revenue growth was driven especially by the global distributor and China sales channels but also the revenue in the US market continued on its growth trajectory. During the quarter, Optomed provided a large device delivery to a Chinese customer and a significant diabetic retinopathy screening solution consisting of Optomed Aurora IQ fundus cameras and related software solutions to a public sector end customer in Valencia, Spain.
The gross margin was 61.6 (93.8) percent. EBITDA was EUR -50 (546) thousand or -2.7 (32.2) percent of revenue. During the comparison period Optomed was granted a loan waiver in the amount of EUR 841 thousand treated as other operating income that had a corresponding positive effect on both gross margin and EBITDA. Gross margin adjusted for grants and other operating income was 61.9 (44.2) percent.
January-September 2023
In January-September 2023, the Devices segment revenue decreased by 3.3 percent to EUR 3,986 (4,122) thousand.
The gross margin decreased to 59.1 percent from 69.7 percent and gross margin adjusted for grants and other operating income was 59.1 (48.4) percent. The improved gross margin was driven especially by the improved margins of the global distributor sales.
EBITDA was EUR -693 (-417) thousand or -17.4 (-10.1) percent of revenue. The lower profitability was due to the previously mentioned extraordinary item of the Q3-2022 boosting the gross margin and, therefore, EBITDA of the comparison period.
Software segment
Optomed has two synergistic business segments: Devices and Software.
The Software segment develops and commercializes screening software for diabetic retinopathy and cancer screening for healthcare organizations. The segment also distributes off-the-shelf products from selected partners to supplement its own solutions and expertise and provides software consultation to support the Devices segment screening solution projects.
EUR, thousand | Q3/2023 | Q3/2022 | Change, % | Q1-Q3/2023 | Q1-Q3/2022 | Change, % | 2022 |
Revenue | 2,393 | 2,003 | 19.4% | 7,454 | 6,525 | 14.2% | 9,263 |
Gross profit * | 1,718 | 1,374 | 25.0% | 5,447 | 4,430 | 22.9% | 6,330 |
Gross margin % * | 71.8% | 68.6% | 73.1% | 67.9% | 68.3% | ||
EBITDA | 636 | 475 | 34.1% | 2,004 | 1,373 | 46.0% | 2,079 |
EBITDA margin *, % | 26.6% | 23.7% | 26.9% | 21.0% | 22.4% | ||
Operating result (EBIT) | 448 | 310 | 44.5% | 1,456 | 890 | 63.7% | 1,431 |
Operating margin (EBIT) *, % | 18.7% | 15.5% | 19.5% | 13.6% | 15.4% |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
July – September 2023
In July-September 2023, the Software segment revenue increased by 19.4 percent to EUR 2,393 (2,003) thousand as the healthcare solutions business continued to grow.
The profitability increased driven by the healthcare solution sales Gross margin increased and was 71.8 (68.6) percent. EBITDA was EUR 636 (475) thousand or 26.6 (23.7) percent of revenue.
January – September 2023
In January-September 2023, the Software segment revenue increased by 14.2 percent to EUR 7,454 (6,525) thousand.
Gross margin increased and it was 73.1 (67.9) percent. EBITDA was EUR 2,004 (1,373) thousand or 26.9 (21.0) percent of revenue. The increased profitability was driven by improved performance of the healthcare solution sales.
Group-wide expenses
Group-wide expenses relate to functions supporting the entire group such as treasury, group accounting, marketing, legal, HR, and IT.
July – September 2023
Group-wide operating expenses amounted to EUR 635 (875) thousand.
January – September 2023
Group-wide operating expenses amounted to EUR 2,335 (2,560) thousand.
Personnel
Number of personnel at the end of the reporting period.
9/2023 | 9/2022 | |
Devices | 47 | 54 |
Software | 48 | 42 |
Group common | 21 | 24 |
Total | 116 | 120 |
Corporate Governance
Optomed complies with Finnish laws and regulations, Optomed’s Articles of Association, the rules of Nasdaq Helsinki and the Finnish Corporate Governance Code 2020 issued by the Securities Market Association of Finland. The code is publicly available at http://cgfinland.fi/en/. Optomed’s corporate governance statement 2022 is available on the company website www.optomed.com/investors/.
Annual General Meeting
The Annual General Meeting held on 10 May 2023 adopted the financial statements for the financial period ended on 31 December 2022 and discharged the members of the Board of Directors and the CEO from liability for the financial period ended on 31 December 2022. The Annual General Meeting decided to reject the remuneration report for governing bodies. The decision made is advisory.
The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that no dividend will be paid for the year 2022.
The number of members of the Board of Directors was confirmed as six. Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam were re-elected as members of the Board and Catherine Calarco and Ty Lee were elected as new members of the Board.
The Annual General Meeting confirmed the annual Board remuneration as follows:
- Chairman of the Board EUR 36,000
- members of the Board EUR 18,000.
In addition, a meeting fee in the amount of EUR 300 is paid to the Chairpersons and EUR 200 to members of the Committees for each Committee meeting. 40 percent of the Board remuneration is paid in Optomed shares and 60 percent in cash. The remuneration will be paid once a year in August, after Optomed’s H1 report has been announced.
The Annual General Meeting decided to re-elect KPMG Oy Ab, a firm of authorized public accountants, as the Company’s auditor. KPMG Oy Ab has informed the Company that Authorized Public Accountant Heidi Hyry acts as the auditor with principal responsibility. Auditor’s remuneration will be paid in accordance with an invoice approved by the Company.
The Annual General Meeting approved the authorization for the Board of Directors to repurchase Optomed’s own shares and to accept them as pledge. Altogether no more than 1,654,135 shares may be repurchased or accepted as pledge. The authorization will be valid until the earlier of the end of the next Annual General Meeting or 18 months from the resolution of the Annual General Meeting.
The Annual General Meeting authorized the Board of Directors to decide on the issuance of shares and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Companies Act. The number of shares to be issued based on this authorization may not exceed 1,654,135. The Board of Directors is authorized to resolve on all terms and conditions of the issuance of shares and special rights entitling to shares, including the right to derogate from the pre-emptive right of the shareholders. The authorization will be valid until the earlier of the end of the next Annual General Meeting or 18 months from the resolution of the Annual General Meeting.
The Annual General Meeting decided to amend the Articles of Association so that the minimum number of the members of the Board of Directors was reduced from five members to four.
Decisions of the Board of Directors:
At its meeting held after the Annual General Meeting, the Board of Directors elected from among its members Petri Salonen as its Chairman. The committee members were elected as follows:
Audit Committee:
- Reijo Tauriainen (Chairman)
- Catherine Calarco
- Anna Tenstam
Remuneration Committee:
- Seppo Mäkinen (Chairman)
- Catherine Calarco
- Ty Lee
Shares and shareholders
The Company has one share series with all shares having the same rights. At the end of the review period Optomed Plc’s share capital consisted of 18,130,397 shares and the Company held 353,973 shares in the treasury which approximately corresponds to 2.1 percent of the total amount of the shares and votes. Additional information with respect to the shares, shareholding and trading can be found on the Company’s website www.optomed.com/investors/.
Directed share issue
Optomed completed a directed share issue consisting of 1,589,042 shares and collected gross proceeds of approximately EUR 4.3 million in September 2023. The main purposes of the Share Issue are to strengthen the Company’s balance sheet and to ensure sufficient financing for the implementation of the Company’s growth strategy especially in the US diabetic retinopathy screening market. The investors include qualified and institutional investors. The subscription price was EUR 2.70 per Share, a discount of approximately 9.09 per cent compared to the representing the last 5-day volume-weighted average trading price (“VWAP”) (EUR 2.97) of the Share up to and including 20 September 2023. The subscription price represents a discount of approximately 8.78 per cent to the closing price of the Company’s share on 20 September 2023. The subscription price will be credited in full to the Company’s reserve for invested unrestricted equity. The new shares were registered in the Finnish Trade Register and trading in the new shares together with the existing shares commenced on Nasdaq Helsinki Ltd on 25 September 2023.
Risks and uncertainties
The key risks and uncertainties are described in the company’s Annual Report 2022 which was published on 2 March 2023. The complete report is available at https://www.optomed.com/investors/. Following risk has been added to the risk position:
Public Procurement
Optomed’s Software segment provides development services also to a Finnish governmental agency under a contract the term of which is ending in the beginning of July 2024. The new contract with the agency is subject to a public procurement process. There is a risk that the Company fails to win the procurement process and the new contract. In case the Company fails to win the new contract, the impact on 2024 revenue is expected to be approximately EUR 1 million.
Audit review
This financial report has not been audited by the company’s auditors.
Financial reporting in 2024
- 15 February 2024 Financial Statement Bulletin for 1 January – 31 December 2023
- 7 May 2024 Interim Report for 1 January – 31 March 2024
- 8 August 2024 Half-Year Financial Report for 1 January – 30 June 2024
- 7 November 2024 Interim Report for 1 January – 30 September 2024
For more information, contact
Sakari Knuutti, CFO
Tel: +358 (0)50 562 4077
E-mail: sakari.knuutti@optomed.com
Juho Himberg, CEO
Tel: +358 (0)40 555 1050
E-mail: juho.himberg@optomed.com
About Optomed
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various eye diseases, such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.
Alternative Performance Measures
Optomed uses certain alternative performance measures (APMs) with the purpose to provide a better understanding of how the business develops. These APMs, as defined, cannot be fully compared with other companies’ APMs.
Alternative Performance Measures | Definition |
Gross profit | Revenue + Other operating income – Materials and services expenses |
Gross margin, % | Gross profit / Revenue |
EBITDA | Operating result before depreciation, amortization and impairment losses |
EBITDA margin, % | EBITDA / Revenue |
Operating result | Profit/loss after depreciation, amortization and impairment losses |
Operating margin, % | Operating result / Revenue |
Adjusted operating result | Operating result excluding items affecting comparability |
Adjusted operating margin, % | Adjusted operating result / Revenue |
Adjusted EBITDA | EBITDA excluding items affecting comparability |
Adjusted EBITDA margin, % | Adjusted EBITDA / Revenue |
Items affecting comparability | Material items outside ordinary course of business including restructuring costs, net gains or losses from sale of business operations or other non-current assets, strategic development projects, external advisory costs related to capital reorganisation, impairment charges on non-current assets incurred in connection with restructurings, compensation for damages and transaction costs related to business acquisitions. |
Net Debt | Interest-bearing liabilities (borrowings from financial institutions, government loans and subordinated loans) – cash and cash equivalents (excl. lease liabilities according to IFRS 16) |
Net Debt / EBITDA (LTM), times | Net Debt / EBITDA (for the last twelve months, LTM) |
Net Debt / Adjusted EBITDA (LTM), times | Net Debt / Adjusted EBITDA (for the last twelve months, LTM) |
Earnings per share | Net result / Weighted average number of outstanding shares |
Equity ratio, % | Total equity / Total assets |
R&D expenses | Employee benefit expenses for R&D personnel and other operational expenses related to R&D activities |
Reconciliation of Alternative Performance Measures
In thousand of Euro | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 |
Revenue | 4,218 | 3,700 | 11,440 | 10,648 | 14,660 |
Other operating income | -6 | 842 | 28 | 879 | 857 |
Material and services | -1,371 | -1,576 | -3,665 | -4,221 | -5,449 |
Gross profit | 2,841 | 2,967 | 7,803 | 7,305 | 10,069 |
Operating result (EBIT) | -603 | -1,411 | -2,655 | -4,227 | -5,097 |
Items affecting comparability | |||||
Specific credit loss percent change from 30 to 50 % | 311 | 0 | 311 | 0 | 0 |
Adjusted EBIT | -291 | -1,411 | -2,343 | -4,227 | -5,097 |
Depreciation, amortization and impairment losses | 554 | -1,557 | 1,631 | 2,622 | 3,145 |
Adjusted EBITDA | 263 | 145 | -713 | -1,604 | -1,952 |
Consolidated income statement
In thousands of euro | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 | |
Revenue | 4,218 | 3,700 | 11,440 | 10,648 | 14,660 | |
Other operating income | -6 | 842 | 28 | 879 | 857 | |
Materials and services | -1,371 | -1,576 | -3,665 | -4,221 | -5,449 | |
Employee benefit expenses | -1,876 | -2,083 | -6,258 | -6,449 | -8,827 | |
Depreciation, amortization and Impairment losses | -554 | -1,557 | -1,631 | -2,622 | -3,145 | |
Other operating expenses | -1,013 | -739 | -2,569 | -2,460 | -3,193 | |
Operating result | -603 | -1,411 | -2,655 | -4,227 | -5,097 | |
Finance income | 317 | 145 | 423 | 563 | 569 | |
Finance expenses | -173 | -130 | -738 | -471 | -1,024 | |
Net finance expenses | 144 | 15 | -315 | 92 | -454 | |
Profit (loss) before income taxes | -459 | -1,397 | -2,970 | -4,135 | -5,551 | |
Income tax expense | 20 | 20 | 59 | 59 | 79 | |
Loss for the period | -439 | -1,377 | -2,911 | -4,075 | -5,472 | |
Loss for the period attributable to | ||||||
Owners of the parent company | -439 | -1,377 | -2,911 | -4,075 | -5,472 | |
Loss per share attributable to owners of the parent company |
||||||
Weighted average number of shares | 16,114,040 | 14,180,928 | 16,114,040 | 14,180,928 | 14,640,697 | |
Basic loss per share (euro) | -0.03 | -0.10 | -0.18 | -0.29 | -0.37 | |
Consolidated condensed comprehensive income statement
In thousands of euro | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 |
Loss for the period | -439 | -1,377 | -2,911 | -4,075 | -5,472 |
Other comprehensive income | |||||
Foreign currency translation difference | -133 | -21 | 111 | -141 | 139 |
Other comprehensive income, net of tax | -133 | -21 | 111 | -141 | 139 |
Total comprehensive loss attributable to Owners of the parent company | -573 | -1,398 | -2,800 | -4,216 | -5,333 |
Consolidated balance sheet
In thousands of euro | September 30, 2023 | September 30, 2022 | Dec 31, 2022 |
ASSETS | |||
Non-current assets | |||
Goodwill | 4,256 | 4,256 | 4,256 |
Development costs | 7,493 | 6,287 | 6,562 |
Customer relationships | 998 | 1,220 | 1,164 |
Technology | 458 | 560 | 534 |
Other intangible assets | 387 | 360 | 379 |
Total intangible assets | 13,592 | 12,683 | 12,895 |
Tangible assets | 747 | 932 | 852 |
Right-of-use assets | 1,069 | 920 | 1,448 |
Deferred tax assets | 17 | 15 | 15 |
Total non-current assets | 15,425 | 14,549 | 15,210 |
Current assets | |||
Inventories | 2,793 | 2,833 | 2,998 |
Trade and other receivables | 3,697 | 4,782 | 4,568 |
Cash and cash equivalents | 9,565 | 5,668 | 8,524 |
Total current assets | 16,054 | 13,283 | 16,090 |
Total assets | 31,479 | 27,832 | 31,300 |
In thousands of euro | September 30, 2023 | September 30, 2022 | Dec 31, 2022 |
EQUITY | |||
Share capital | 80 | 80 | 80 |
Share premium | 504 | 504 | 504 |
Reserve for invested non-restricted equity | 50,936 | 43,137 | 46,896 |
Translation differences | 162 | -228 | 51 |
Retained earnings | -27,085 | -21,803 | -21,717 |
Profit (loss) for the financial year | -2,911 | -4,075 | -5,472 |
Total equity | 21,686 | 17,613 | 20,342 |
LIABILITIES | |||
Non-current liabilities | |||
Borrowings from financial institutions | 1,851 | 3,579 | 3,380 |
Government loans | 837 | 1,030 | 906 |
Lease liabilities | 595 | 538 | 1,058 |
Deferred tax liabilities | 329 | 406 | 387 |
Total Non-current liabilities | 3,613 | 5,553 | 5,731 |
Current liabilities | |||
Borrowings from financial institutions | 1,794 | 596 | 794 |
Government loans | 193 | 193 | 193 |
Lease liabilities | 505 | 400 | 412 |
Trade and other payables | 3,687 | 3,477 | 3,828 |
Total current liabilities | 6,180 | 4,666 | 5,227 |
Total liabilities | 9,793 | 10,218 | 10,957 |
Total equity and liabilities | 31,479 | 27,832 | 31,300 |
Consolidated statement of changes in shareholders’ equity
Equity attributable to owners of the parent company
In thousands of euro | Share capital | Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
Balance at January 1, 2023 | 80 | 504 | 46,896 | 51 | -27,189 | 20,342 |
Comprehensive income | ||||||
Loss for the period | -2,911 | -2,911 | ||||
Other comprehensive income | ||||||
Translation differences | 111 | 111 | ||||
Total comprehensive income for the period | 111 | -2,911 | -2,800 | |||
Share issue | 4,023 | 4,023 | ||||
Share options | 16 | 105 | 121 | |||
Total transactions with owners of the company | 4,039 | 105 | 4,144 | |||
Balance at September 30, 2023 | 80 | 504 | 50,936 | 162 | -29,995 | 21,686 |
Equity attributable to owners of the parent company
In thousands of euro | Share capital | Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
Balance at January 1, 2022 | 80 | 504 | 38,526 | -88 | -21,970 | 17,052 |
Comprehensive income | ||||||
Loss for the period | -4,075 | -4,075 | ||||
Other comprehensive income | ||||||
Translation differences | -141 | -141 | ||||
Total comprehensive income for the period | -141 | -4,075 | -4,216 | |||
Share issue | 4,611 | 4,611 | ||||
Share options | 167 | 167 | ||||
Total transactions with owners of the company | 4,611 | 167 | 4,778 | |||
Other adjustments | 0 | |||||
Balance at September 30, 2022 | 80 | 504 | 43,137 | -228 | -25,878 | 17,613 |
Equity attributable to owners of the parent company
In thousands of euro | Share capital | Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
Balance at January 1, 2022 | 80 | 504 | 38,526 | -88 | -21,970 | 17,052 |
Comprehensive income | ||||||
Loss for the period | -5,472 | -5,472 | ||||
Other comprehensive income | ||||||
Translation differences | 139 | 139 | ||||
Total comprehensive income for the period | 139 | -5,472 | -5,333 | |||
Share issue | 8,371 | 8,371 | ||||
Share options | 253 | 253 | ||||
Total transactions with owners of the company | 8,371 | 253 | 8,624 | |||
Balance at December 31, 2022 | 80 | 504 | 46,896 | 51 | -27,189 | 20,342 |
Consolidated cash flow statement
In thousands of euro | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 |
Cash flows from operating activities | |||||
Loss for the financial year | -439 | -1,377 | -2,911 | -4,075 | -5,472 |
Adjustments: | |||||
Depreciation, amortization and impairment
losses |
554 | 1,557 | 1,631 | 2,622 | 3,145 |
Finance income and finance expenses | -79 | 37 | 423 | 0 | 618 |
Other adjustments | 366 | -782 | 311 | -752 | -770 |
Cash flows before change in net working capital | 402 | -565 | -546 | -2,204 | -2,479 |
Change in net working capital: | |||||
Change in trade and other receivables
(increase (-) / decrease (+)) |
611 | 496 | 597 | 64 | 204 |
Change in inventories
(increase (-) / decrease (+)) |
187 | 345 | 173 | 159 | -68 |
Change in trade and other payables
(increase (+) / decrease (-)) |
-334 | -725 | -175 | 20 | 172 |
Cash flows before finance items | 866 | -449 | 50 | -1,962 | -2,171 |
Interest paid | -76 | -38 | -128 | -60 | -76 |
Other finance expenses paid | -23 | -17 | -42 | -72 | -123 |
Net cash from operating activities (A) | 767 | -504 | -120 | -2,093 | -2,370 |
Cash flows from investing activities | |||||
Capitalization of development expenses | -549 | -449 | -1,672 | -1,729 | -2,249 |
Acquisition of tangible assets | -67 | -349 | -156 | -742 | -780 |
Net cash used in investing activities (B) | -615 | -797 | -1,828 | -2,471 | -3,029 |
Cash flows from financing activities | |||||
Proceeds from share subscriptions | 4,294 | 7 | 4,310 | 4,952 | 9,012 |
Share issue transaction costs | -318 | 0 | -318 | -382 | -682 |
Repayment of loans and borrowings | -132 | -73 | -598 | -880 | -912 |
Repayment of lease liabilities | -123 | -106 | -370 | -310 | -415 |
Net cash from financing activities (C) | 3,721 | -172 | 3,024 | 3,380 | 7,003 |
Net cash from (used in) operating, investing and financing activities (A+B+C) | 3,872 | -1,473 | 1,077 | -1,184 | 1,605 |
Cash and cash equivalents at beginning of period | 5,691 | 7,079 | 8,524 | 6,804 | 6,804 |
Effect of movements in exchange rate on cash held | 2 | 63 | -36 | 48 | 115 |
Cash and cash equivalents at end of period | 9,565 | 5,668 | 9,565 | 5,668 | 8,524 |
Selected notes
Corporate information and basis of accounting
Corporate information
Optomed is a Finnish medical technology group (hereafter ‘Optomed’ or ‘Group’) that specialises in handheld fundus cameras and solutions for screening of blinding eye diseases, established in 2004.
The Group’s parent company, Optomed Plc (hereafter the ‘Company’), is a Finnish public limited liability company established under the laws of Finland, and its business ID is 1936446-1. It is domiciled in Oulu, Finland and the Company’s registered address is Yrttipellontie 1, 90230 Oulu, Finland.
All presented figures have been rounded so the sum of the individual figures may differ from the presented total figure.
This report has been authorized for issue by the company`s board of directors.
Reportable segments
Q3/2023
In thousands of euro | Devices | Software | Group
Admin |
Total |
External revenue | 1,825 | 2,393 | 0 | 4,218 |
Net operating expenses | -701 | -675 | 0 | -1,376 |
Margin | 1,124 | 1,718 | 0 | 2,841 |
Depreciation and amortization | -363 | -189 | -3 | -554 |
Other expenses | -1,174 | -1,081 | -635 | -2,890 |
Operating result | -413 | 448 | -637 | -603 |
Finance items | 0 | 0 | 144 | 144 |
Loss before tax expense | -413 | 448 | -494 | -459 |
Q3/2022
In thousands of euro | Devices | Software | Group
Admin |
Total |
External revenue | 1,697 | 2,003 | 0 | 3,700 |
Net operating expenses | -105 | -629 | 0 | -734 |
Margin | 1,592 | 1,374 | 0 | 2,967 |
Depreciation and amortization | -1,390 | -165 | -2 | -1,557 |
Other expenses | -1,046 | -900 | -875 | -2,821 |
Operating result | -844 | 310 | -877 | -1,411 |
Finance items | 0 | 0 | 15 | 15 |
Loss before tax expense | -844 | 310 | -863 | -1,397 |
Q1-Q3/2023
In thousands of euro | Devices | Software | Group
Admin |
Total |
External revenue | 3,986 | 7,454 | 0 | 11,440 |
Net operating expenses | -1,630 | -2,007 | 0 | -3,637 |
Margin | 2,356 | 5,447 | 0 | 7,803 |
Depreciation and amortization | -1,076 | -548 | -7 | -1,631 |
Other expenses | -3,050 | -3,443 | -2,335 | -8,827 |
Operating result | -1,769 | 1,456 | -2,342 | -2,655 |
Finance items | 0 | 0 | -315 | -315 |
Loss before tax expense | -1,769 | 1,456 | -2,657 | -2,970 |
Q1-Q3/2022
In thousands of euro | Devices | Software | Group
Admin |
Total |
External revenue | 4,122 | 6,525 | 0 | 10,648 |
Net operating expenses | -1,248 | -2,095 | 0 | -3,342 |
Margin | 2,875 | 4,430 | 0 | 7,305 |
Depreciation and amortization | -2,133 | -483 | -6 | -2,622 |
Other expenses | -3,292 | -3,057 | -2,560 | -8,909 |
Operating result | -2,550 | 890 | -2,566 | -4,227 |
Finance items | 0 | 0 | 92 | 92 |
Loss before tax expense | -2,550 | 890 | -2,474 | -4,135 |
2022
In thousands of euro | Devices | Software | Group
Admin |
Total |
External revenue | 5,398 | 9,263 | 0 | 14,660 |
Net operating expenses | -1,659 | -2,933 | 0 | -4,592 |
Margin | 3,738 | 6,330 | 0 | 10,069 |
Depreciation and amortization | -2,489 | -649 | -8 | -3,145 |
Other expenses | -4,408 | -4,251 | -3,361 | -12,020 |
Operating result | -3,159 | 1,431 | -3,368 | -5,097 |
Finance items | 0 | 0 | -454 | -454 |
Loss before tax expense | -3,159 | 1,431 | -3,823 | -5,551 |
Other operating income
In thousands of euro | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 | |
Other operating income | -6 | 842 | 28 | 879 | 857 | |
Total | -6 | 842 | 28 | 879 | 857 | |
Other operating expenses
Other operating expenses | Q3/2023 | Q3/2022 | Q1-Q3/2023 | Q1-Q3/2022 | 2022 |
Sales and marketing | -111 | -200 | -450 | -578 | -784 |
Research and development | -54 | -36 | -186 | -298 | -361 |
General and administration | -849 | -503 | -1,933 | -1,584 | -2,049 |
Total operating expenses | -1,013 | -739 | -2,569 | -2,460 | -3,193 |
Other operating expenses also comprise changes in expected credit losses and realized credit losses.
Exposure to credit risk and loss allowance
Optomed considers it has heightened risk regarding Chinese customer’s trade receivables. The credit risk concentration has been formed and is associated with an increased credit loss risk due to overdue trade receivables. Specific loss allowance weighted average loss rate% increased from 30% to 50%.
In thousands of euro | Gross carrying amount | Weighted av.
loss rate% |
Loss
allowance |
At September 30, 2023 | |||
Current (not past due) | 1,647 | 0.5% | 8 |
Past due | |||
1-30 days | 38 | 1.5% | 1 |
31-60 days | 83 | 4% | 3 |
61-90 days | 125 | 9% | 11 |
More than 90 days past due | 306 | 12% | 37 |
Specific loss allowance | 1,556 | 50% | 778 |
Total | 3,756 | 838 |
In thousands of euro | Gross carrying amount | Weighted av.
loss rate% |
Loss
allowance |
At September 30, 2022 | |||
Current (not past due) | 1,572 | 0.5% | 8 |
Past due | |||
1-30 days | 144 | 1.5% | 2 |
31-60 days | 135 | 4% | 5 |
61-90 days | 12 | 9% | 1 |
More than 90 days past due | 37 | 12% | 4 |
Specific loss allowance | 2,211 | 30% | 663 |
Total | 4,112 | 684 |
In thousands of euro | Gross carrying amount | Weighted av.
loss rate% |
Loss
allowance |
At December 31, 2022 | |||
Current (not past due) | 1,664 | 0.5% | 8 |
Past due | |||
1-30 days | 161 | 1.5% | 2 |
31-60 days | 7 | 4% | 0 |
61-90 days | 29 | 9% | 3 |
More than 90 days past due | 12 | 12% | 1 |
Specific loss allowance | 1,962 | 30% | 589 |
Total | 3,836 | 604 |
Financial liabilities
In thousands of euro | 30.9.2023 | 30.9.2022 | 31.12.2022 |
Non-current financial liabilities | |||
Borrowings from financial institutions | 1,851 | 3,579 | 3,380 |
Government loans | 837 | 1,030 | 906 |
Lease liabilities | 595 | 538 | 1,058 |
Total | 3,284 | 5,147 | 5,344 |
|
|||
Current financial liabilities | |||
Borrowings from financial institutions | 1,794 | 596 | 794 |
Government loans | 193 | 193 | 193 |
Lease liabilities | 505 | 400 | 412 |
Trade payables | 990 | 1,004 | 869 |
Total | 3,482 | 2,193 | 2,268 |
Total financial liabilities | 6,766 | 7,340 | 7,612 |
Fair values – financial liabilities measured at amortized cost.
Optomed considers that the carrying amounts of the financial liabilities measured at amortized cost substantially equal to their fair values.
Events after the review period
No material events after the reporting period.
Read the full report here.